3) Higher IL-6 in both groups of AD patients vs. healthy controls reflecting ongoing innate/inflammatory activation under both conditions.<h4>Conclusion</h4>Dupilumab effectively suppresses Th2 signaling but does not fully normalize immune balance<b>;</b> residual Th17 and innate activity persists. This evidence concerns the gene IL6 and Alzheimer disease.